



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

- |   |   |
|---|---|
| <p>(15) Correction information:<br/><b>Corrected version no 1 (W1 B1)</b><br/><b>INID code(s) 54</b></p> <p>(48) Corrigendum issued on:<br/><b>08.06.2005 Bulletin 2005/23</b></p> <p>(45) Date of publication and mention<br/>of the grant of the patent:<br/><b>06.04.2005 Bulletin 2005/14</b></p> <p>(21) Application number: <b>95910239.3</b></p> <p>(22) Date of filing: <b>09.02.1995</b></p> | <p>(51) Int Cl.7: <b>A61K 31/24</b>, A61K 31/42,<br/>A61K 31/275, A61K 31/415,<br/>A61K 31/495, C07C 211/45,<br/>C07C 255/01, C07D 209/18,<br/>C07D 231/38, C07D 241/36,<br/>C07C 255/41, C07D 239/93</p> <p>(86) International application number:<br/><b>PCT/US1995/001751</b></p> <p>(87) International publication number:<br/><b>WO 1995/021613 (17.08.1995 Gazette 1995/35)</b></p> |
|---|---|

(54) **COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS**

VERBINDUNGEN ZUR BEHANDLUNG VON ERKRANKUNGEN, DIE MIT DER VASCULOGENESE UND/ODER ANGIOGENESE IN ZUSAMMENHANG STEHEN.

COMPOSES DESTINES AU TRAITEMENT DE TROUBLES ASSOCIES A LA VASCULOGENESE ET/OU A L'ANGIOGENESE

- |   |  |
|---|--|
| <p>(84) Designated Contracting States:<br/><b>DE FR GB</b></p> <p>(30) Priority: <b>09.02.1994 US 193829</b></p> <p>(43) Date of publication of application:<br/><b>18.12.1996 Bulletin 1996/51</b></p> <p>(73) Proprietors:<br/>• <b>Sugen, Inc.</b><br/><b>Redwood City, CA 94063 (US)</b><br/>• <b>YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM</b><br/><b>Jerusalem 91042 (IL)</b></p> <p>(72) Inventors:<br/>• <b>GAZIT, Aviv</b><br/><b>96190 Jerusalem (IL)</b><br/>• <b>LEVITZKI, Alexander</b><br/><b>Patomic, MA 02854 (US)</b><br/>• <b>APP, Harald</b><br/><b>Hillsborough, CA 94010 (US)</b><br/>• <b>TANG, Cho, Peng</b><br/><b>Moraga, CA 94556 (US)</b><br/>• <b>MCMAHON, Gerald, M.</b><br/><b>San Francisco, CA 94109 (US)</b></p> | <p>(74) Representative: <b>Jaenichen, Hans-Rainer, Dr.</b><br/><b>Vossius &amp; Partner,</b><br/><b>Postfach 86 07 67</b><br/><b>81634 München (DE)</b></p> <p>(56) References cited:<br/><b>EP-A- 0 520 722</b>                      <b>EP-A- 0 665 013</b><br/><b>WO-A-95/19169</b>                      <b>DE-B- 1 135 471</b><br/><b>JP-A- 55 167 205</b>                      <b>JP-A- 60 097 964</b></p> <ul style="list-style-type: none"> <li>• <b>J. MED. CHEM., Volume 26, issued 1983, STOUT et al., "Synthesis and Antiarrhythmic and Parasympatholytic Properties of Substituted Phenols. 1. Heteroarylamine Derivatives", pages 808-813.</b></li> <li>• <b>CHEMICAL ABSTRACTS, Volume 117, issued 1990, KOKOSI et al., "Process for Producing Imidazo[5,1-Beta]Quinazolin-9-one Derivatives and Pharmaceutically Acceptable Salts Thereof, as well as Pharmaceutical Compositions Comprising such as Active Ingredient", Abstract No. 212519; &amp; HU,A, 59 411.</b></li> <li>• <b>ANTI-CANCER DRUGS, Volume 5, issued 1994, KAUR et al., "Tyrphostin Induced Growth Inhibition: Correlation with Effect on P210 bcr-abl Autokinase Activity in K562 Chronic Myelogenous Leukemia", pages 213-222.</b></li> </ul> |
|---|--|

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- JOURNAL F. PRAKT. CHEM., Volume 329, No. 1, issued 1987, VOGEL et al., "Synthese von 4-Substituierten 1,2,3-Triazolo[1,5-a]-Chinoxalinen", pages 101-107.
- JOURNAL OF MEDICINAL CHEMISTRY, Volume 36, issued 1993, GAZIT et al., "Tyrphostins. 3. Structure-Activity Relationship Studies of Alpha-Substituted Benzylidenemalononitrile 5-S-Aryltyrphostins", pages 3556-3564.
- BIOCHEMISTRY, Volume 32, No. 17, issued 1993, OHMACHI et al., "The Tyrosine Kinase Inhibitor Tyrphostin Blocks the Cellular Actions of Nerve Growth Factor", pages 4650-4658.
- BIOCHIMICA ET BIOPHYSICA ACTA, Volume 935, issued 1988, MIYOSHI et al., "Quantitative Analysis of the Uncoupling Activity of Substituted Phenols with Mitochondria from Flight Muscles of House Flies", pages 312-321.
- CANADIAN JOURNAL OF CHEMISTRY, Volume 63, issued 1985, MARLIN, "Resonance Raman Study of Phenylhydrazonopropanedinitriles", pages 1840-1844.